The DLK2 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human cervical adenocarcinoma HeLa cell line, in which the DLK2 gene has been disrupted to create a loss-of-function model. This polyclonal pool provides a heterogeneous knockout background that avoids clonal artifacts and enables robust functional studies of DLK2-dependent processes. The product is designed for researchers investigating the non-canonical Notch signaling pathway and its roles in cell differentiation, adipogenesis, and neurogenesis.
The host cell line, HeLa, is an immortalized, adherent epithelial cell line isolated from a human cervical adenocarcinoma. It is HPV18-positive and represents one of the most extensively used models in cancer research and cell biology. HeLa cells exhibit high transfection efficiency, rapid proliferation, and well-characterized signaling networks, making them an ideal platform for CRISPR-based gene disruption and subsequent phenotypic analyses.
DLK2 encodes a transmembrane EGF-like protein that functions as a non-canonical inhibitor of Notch signaling. It competes with canonical ligands such as DLL1 and JAG1 for binding to NOTCH1 and NOTCH2 receptors, thereby repressing HES1 transcription and altering downstream differentiation programs. DLK2 is regulated by upstream factors including cAMP signaling, the glucocorticoid receptor, and transcription factors CEBPB and CEBPD. Its activity modulates key downstream targets like PPARG, CEBPA, FABP4, adiponectin, and TUBB3, thereby promoting adipogenic and neurogenic differentiation. DLK2 also interacts with DLK1, a related EGF-like protein with opposing effects on Notch signaling.
In the HeLa cell context, DLK2 knockout enables dissection of non-canonical Notch signaling pathways that are often dysregulated in cancer. HeLa cells provide a relevant epithelial background for examining how DLK2 loss influences cell fate decisions, proliferation, and differentiation. This model is particularly valuable given HeLa’s well-documented signaling responsiveness and the established crosstalk between Notch and other pathways implicated in cervical carcinogenesis.
Researchers can employ this polyclonal knockout product in a variety of assays including Western blotting to assess protein expression changes, RT-qPCR for transcriptional profiling, Notch luciferase reporter assays to measure pathway activity, adipocyte differentiation assays with Oil Red O staining, and neurogenic differentiation assays via TUBB3 immunofluorescence. Additional applications encompass co-immunoprecipitation to study protein interactions, flow cytometry for surface marker analysis, and RNA-seq for global transcriptomic evaluation. These cells are suitable for functional Notch signaling studies, adipogenesis and neurogenesis research, cancer cell signaling investigations, and drug target validation. For further information, please contact Ascent Research.
